Amgen

SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, May 31, 2022
Oncology, Health, Infectious Diseases, Stem Cells, Genetics, Clinical Trials, Biotechnology, Senior, Immunology, Disease, Autoimmunity, Doctor of Philosophy, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Asthma, Degenerative disease, MD, Hospital, Leadership, Patient, Biology, Infection, Immune tolerance, Internal medicine, Risk, Therapy, Gilead Sciences, COVID-19, National Jewish Center for Learning and Leadership, BS, AstraZeneca, University, Epstein–Barr virus, University of Nebraska Medical Center College of Dentistry, Rheumatoid arthritis, ST, Baylor University, Confidentiality, Cell, Amgen, Cancer, NYSE, Annual report, SQZ, CEO, Pharmaceutical industry, Vaccine, Ionis

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Marshelle Smith Warren, M.D., as Chief Medical Officer.

Key Points: 
  • SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Marshelle Smith Warren, M.D., as Chief Medical Officer.
  • Previously, she was Chief Medical Officer and Senior Vice President of R&D at Viracta Therapeutics, where she led the development of investigational therapeutics for the treatment of Epstein-Barr virus associated lymphoid malignancies.
  • I am very excited to be joining a dedicated team focused on developing a new generation of impactful cell therapies for diseases with significant unmet need, said Marshelle Smith Warren, M.D., Chief Medical Officer at SQZ Biotechnologies.
  • SQZ Biotechnologies cell therapy programs seek to generate activating or tolerizing target-specific immune responses with potential impact across many diseases.

Cell and Gene Therapy Global Market Report 2022 Featuring Gilead Sciences, Bristol-Myers Squibb, Novartis, Amgen, Merck, Organogenesis, Dendreon, Vericel, Bluebird Bio and Fibrocell Science - ResearchAndMarkets.com

Retrieved on: 
Friday, May 27, 2022
Biotechnology, Genetics, Health, Lymphoma, Multiple myeloma, Protest and strikes of the CGT union 2021, Genome, Medicine, Bristol Myers Squibb, Dermatology, Patient, Acute lymphoblastic leukemia, Novartis, COVID-19, Merck, Adult, Cell, Dendreon, Canadian Aviation Regulations, CGT, Gene, FDA, B-cell lymphoma, Hospital, Budget, Organization, Tisagenlecleucel, ALL, CAR, Amgen, Growth, Application, Gilead Sciences, Medical device, Pharmaceutical industry, Vaccine, Fine chemical

Major players in the cell and gene therapy market are Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon, Vericel, Bluebird Bio and Fibrocell Science.

Key Points: 
  • Major players in the cell and gene therapy market are Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon, Vericel, Bluebird Bio and Fibrocell Science.
  • The cell and gene therapy market consist of sales of cell and gene therapies by entities (organizations, sole traders and partnerships) that develop cell and gene therapies.
  • The main types of products in cell and gene therapy are cell therapy and gene therapy.
  • Steady investment and consolidation in cell and gene therapies contributed to the growth of the cell and gene therapy (CGT) market.

Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022

Retrieved on: 
Friday, May 27, 2022
Cancer, Ascites, Part, Achievement, Company, Neutropenia, BMS, Neoplasm, CPI, Doctor of Philosophy, Kite Pharma, Antibody-drug conjugate, Patient, Wuxi, ADC, OXFORD, Pharmacokinetics, Society, American Society of Clinical Oncology, Cmax, Adult, SAN, DLT, Clinical trial, GCSF, Toxicity, CD205, Safety, HIV disease progression rates, Cytotoxicity, ASCO, Boehringer Ingelheim, Lung, Therapy, PD, OBT, Immune system, Infrared spectroscopy correlation table, Amgen, CEO, ADCC, Granulocyte, Pharmaceutical industry, Medical imaging, Fine chemical, IO

Company has advanced OBT076 into single agent expansion cohorts in both checkpoint- and chemotherapy-nave and resistant patients.

Key Points: 
  • Company has advanced OBT076 into single agent expansion cohorts in both checkpoint- and chemotherapy-nave and resistant patients.
  • Subsequent disease-specific Phase 2a trials are planned in non-small cell lung, ovarian and gastric cancer patients.
  • OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies.
  • For more information on Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com

Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022

Retrieved on: 
Friday, May 27, 2022
Cancer, Ascites, Part, Achievement, Company, Neutropenia, BMS, Neoplasm, CPI, Doctor of Philosophy, Kite Pharma, Antibody-drug conjugate, Patient, Wuxi, ADC, OXFORD, Pharmacokinetics, Society, American Society of Clinical Oncology, Cmax, Adult, SAN, DLT, Clinical trial, GCSF, Toxicity, CD205, Safety, HIV disease progression rates, Cytotoxicity, ASCO, Boehringer Ingelheim, Lung, Therapy, PD, OBT, Immune system, Infrared spectroscopy correlation table, Amgen, CEO, ADCC, Granulocyte, Pharmaceutical industry, Medical imaging, Fine chemical, IO

Company has advanced OBT076 into single agent expansion cohorts in both checkpoint- and chemotherapy-nave and resistant patients.

Key Points: 
  • Company has advanced OBT076 into single agent expansion cohorts in both checkpoint- and chemotherapy-nave and resistant patients.
  • Subsequent disease-specific Phase 2a trials are planned in non-small cell lung, ovarian and gastric cancer patients.
  • OBT has a strong oncology focused management team and board with significant experience in developing IO and antibody-based therapies.
  • For more information on Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com

Global Dermatologicals Market Report to 2030 - Rising Awareness Among Individuals Regarding Skin Diseases is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 26, 2022
Health, Pharmaceutical, Department, Knowledge, American Academy, Criticism of the Food and Drug Administration, Population, Medicine, Skin, Apremilast, Food, Patient, Hives, Government, Dermatology, Association, COVID-19, FDA, Rosacea, Psoriasis, Awareness, Program, Safety, Route, Adoption, Administration, Acne, CAGR, Amgen, Growth, Prevalence, Atopic dermatitis, Pharmaceutical industry

This factors is expected to notably contribute toward the growth of the global dermatologicals market.

Key Points: 
  • This factors is expected to notably contribute toward the growth of the global dermatologicals market.
  • However, availability of alternative treatment options for acne and other skin diseases hinders the market growth.
  • On the contrary, increase in awareness among population about various treatments available for skin diseases augments the growth of the dermatologicals market.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.

CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors

Retrieved on: 
Thursday, May 26, 2022
Risk, Nasdaq, TCB, Tumor microenvironment, Leadership, Breast cancer, Patient, AbbVie, TCBS, ADC, Therapy, Clinical trial, COVID-19, CD3, Bristol Myers Squibb, Sarah Cannon Research Institute, CD166, Research, SAN, CD71, Technology, Safety, EGFR, Conjugation, LinkedIn, Twitter, Head, Amgen, Cancer, United, Bi-specific T-cell engager, GLOBE, Pharmaceutical industry, Medical imaging, Vaccine, MSCI

SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904 ( NCT05387265 ).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904 ( NCT05387265 ).
  • This study underscores our commitment to destroying cancer differently and bolsters our leadership in the field of conditional activation in oncology.
  • We look forward to exploring CX-904 in solid tumors, said Meredith Pelster, M.D., MSCI, a study investigator at Sarah Cannon Research Institute at Tennessee Oncology.
  • Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN

Retrieved on: 
Thursday, May 26, 2022
Company, News, NASDAQ, IRS, LLP, Amgen, Pomerantz, Internal Revenue Service, GLOBE, Private investigator

NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. (Amgen or the Company) (NASDAQ: AMGN).

Key Points: 
  • NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. (Amgen or the Company) (NASDAQ: AMGN).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Amgen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Healthcare Technology Veteran Greg Nagy Joins MDisrupt as Chief Operating Officer

Retrieved on: 
Wednesday, May 25, 2022
Other Health, Health, Data Management, Technology, Managed Care, Aurora, MBA, Engineering, UC, Biological engineering, Vertex Pharmaceuticals, Leadership, Patient, Pepperdine University, University of California, San Diego, Instinct, Efficiency, Industry, Global marketing, Biotechnology, Bausch Health, Technology, Aurora Biosciences, LinkedIn, Twitter, Amgen, Growth, CEO, Management

MDisrupt , a digital health intelligence company, announced today that Greg Nagy has been appointed as Chief Operating Officer.

Key Points: 
  • MDisrupt , a digital health intelligence company, announced today that Greg Nagy has been appointed as Chief Operating Officer.
  • Mr. Nagy is a veteran global commercial executive in the life sciences and medical technology industries.
  • He previously served as Chief Marketing Officer at Drawbridge Health and Vice President of Global Marketing at Topcon Eyecare.
  • Hiring a full-time chief operating officer is essential as we become a product-led and technology focused company.

Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in combination with Agenus' CPI Balstilimab

Retrieved on: 
Wednesday, May 25, 2022
Cancer, Company, BMS, Neoplasm, CPI, Infection, CD205, GMP, ImmunoGen, Doctor of Philosophy, Kite Pharma, Antibody-drug conjugate, Patient, Wuxi, ADC, PD-1, OXFORD, Primary tumor, Therapy, Clinical trial, Mink, Research, SAN, Partnership, Ovarian cancer, Boehringer Ingelheim, Lung, CMO, Twitter, Immune system, Amgen, OBT, MD, CA, CEO, Pharmaceutical industry, Medical imaging, Vaccine, IO

OBT plans to evaluate the clinical efficacy of OBT076 in combination with Agenus proprietary CPI, balstilimab.

Key Points: 
  • OBT plans to evaluate the clinical efficacy of OBT076 in combination with Agenus proprietary CPI, balstilimab.
  • Balstilimab is an PD-1 blocking antibody currently in clinical development in several solid tumor indications.
  • "I am very excited about our new partnership with Agenus, which will allow us to progress the clinical development of OBT076 in combination with balstilimab," said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics.
  • "We look forward to collaborating with Oxford BioTherapeutics to bring this novel combination to patients," said Steven O'Day, MD, Chief Medical Officer of Agenus.

Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in combination with Agenus' CPI Balstilimab

Retrieved on: 
Wednesday, May 25, 2022
Cancer, Company, BMS, Neoplasm, CPI, Infection, CD205, GMP, ImmunoGen, Doctor of Philosophy, Kite Pharma, Antibody-drug conjugate, Patient, Wuxi, ADC, PD-1, OXFORD, Primary tumor, Therapy, Clinical trial, Mink, Research, SAN, Partnership, Ovarian cancer, Boehringer Ingelheim, Lung, CMO, Twitter, Immune system, Amgen, OBT, MD, CA, CEO, Pharmaceutical industry, Medical imaging, Vaccine, IO

OBT plans to evaluate the clinical efficacy of OBT076 in combination with Agenus proprietary CPI, balstilimab.

Key Points: 
  • OBT plans to evaluate the clinical efficacy of OBT076 in combination with Agenus proprietary CPI, balstilimab.
  • Balstilimab is an PD-1 blocking antibody currently in clinical development in several solid tumor indications.
  • "I am very excited about our new partnership with Agenus, which will allow us to progress the clinical development of OBT076 in combination with balstilimab," said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics.
  • "We look forward to collaborating with Oxford BioTherapeutics to bring this novel combination to patients," said Steven O'Day, MD, Chief Medical Officer of Agenus.